Because a small number of hepatic LDL receptors lead to elevated plasma LDL levels, the development of drugs that can increase available LDL receptors such as the PCSK9 inhibitor is one of the strategies for dyslipidemia treatment. Here, PCSK9 is linked to metabolic syndrome.